预约演示
更新于：2025-09-10
Tirzepatide
替尔泊肽
更新于：2025-09-10
概要
基本信息
药物类型 合成多肽 |
别名 Tirzepatide (USAN)、TZP、ZEHP-bownd + [14] |
作用方式 激动剂 |
作用机制 GIPR激动剂(胃抑素受体激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2022-05-13), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 10195070
来源: *****
关联
160
项与 替尔泊肽 相关的临床试验NCT06180616
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled Trial
NCT06820281
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)
NCT06651177
NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)
100 项与 替尔泊肽 相关的临床结果
登录后查看更多信息
100 项与 替尔泊肽 相关的转化医学
登录后查看更多信息
100 项与 替尔泊肽 相关的专利（医药）
登录后查看更多信息
1,383
项与 替尔泊肽 相关的文献（医药）2025-12-31European Clinical Respiratory Journal
Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
Review
作者: Balbaa, Elsayed ; Altobaishat, Obieda ; Farid Gadelmawla, Ahmed ; Turkmani, Mustafa ; Abouzid, Mohamed
Background:
Obstructive sleep apnea (OSA) is a common condition affecting around one billion people worldwide. Emerging evidence from recent studies suggests that Glucagon-like peptide 1 receptor (GLP-1) agonists may reduce OSA severity. Hence, this meta-analysis aims to evaluate the efficacy and safety of GLP-1 agonists in patients with OSA.
Methods:
Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, EMBASE, Cochrane Library, Scopus, and Web of Science) to identify eligible studies reported up to 24 June 2024. Using Review Manager software, we reported outcomes as risk ratios (RRs) or mean difference (MD) and confidence intervals (CIs). The protocol for this review has been registered and published in PROSPERO with the ID (CRD42024562853).
Results:
The meta-analysis included three randomized controlled trials with 828 patients. Pooled analysis of patients administered GLP-1 agonists or tirzepatide showed improvement in Apnea/Hypopnea Index (MD -16.57 events per hour, 95% CI [-27.41, -5.73], p = 0.003), weight reduction (MD -12.71%, 95% CI [-21.38, -4.03], p = 0.004), and systolic blood pressure (MD -4.93 mmHg,95% CI [-7.67, -2.19], p = 0.0004). Tirzepatide showed a reduction in high-sensitivity C-reactive protein (MD -0.89 mg/dl, 95% CI [-1.25, -0.54], p < 0.0001) and sleep apnea-specific hypoxic burden (MD -66.21%/min, 95% CI [-81.75, -50.67], p < 0.0001). Despite the heterogeneity observed in the AHI and weight, it was resolved, and the results were consistent. GLP-1 agonists/tirzepatide showed comparable outcomes concerning diastolic blood pressure (MD -1.34 mmHg, 95% CI [-2.80, 0.12], p = 0.07). No significant serious adverse events were observed for GLP-1 agonists/tirzepatide, but it was associated with a higher incidence of gastrointestinal adverse events.
Conclusion:
GLP-1 agonists, including tirzepatide, improved Apnea/Hypopnea Index, weight, and systolic blood pressure in adults with moderate-to-severe OSA. However, the evidence remains limited to two published studies comprising three randomized controlled trials using different pharmacological agents. Consequently, further research is needed before firm conclusions can be drawn.
2025-12-31Journal of Pharmaceutical Policy and Practice
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
Article
作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.
Background:
High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.
Methods:
We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.
Results:
We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.
Conclusion:
This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.
2025-12-01Current Cardiovascular Risk Reports
Triple Agonism Based Therapies for Obesity
Review
作者: Papamargaritis, Dimitris ; Surti, Farhaana ; Goldney, Jonathan ; Hamza, Malak ; Davies, Melanie J
Abstract:
Purpose of the Review:
Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management. Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the way for next-generation incretin-based therapies. Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors represent a promising next step. This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate.
Recent Findings:
Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D. Retatrutide achieved up to 24.2% mean weight loss after 48 weeks in individuals with obesity and 16.9% in those with T2D after 36 weeks. In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%. Retatrutide also improved multiple cardiometabolic parameters, including blood pressure, lipids, waist circumference, and liver fat (82% reduction in hepatic steatosis). Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed. A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D. Other unimolecular triple agonists and combination regimens involving tirzepatide with additional mono agonists are also in development.
Summary:
Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
100 项与 替尔泊肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肥胖通气不足综合征 | 中国 | 2025-06-30 | |
| 阻塞性睡眠呼吸暂停综合征 | 美国 | 2024-12-20 | |
| 肥胖 | 美国 | 2023-11-08 | |
| 超重 | 美国 | 2023-11-08 | |
| 体重增加 | 澳大利亚 | 2022-12-23 | |
| 2型糖尿病 | 美国 | 2022-05-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 射血分数保留型心力衰竭 | 申请上市 | 中国 | 2024-11-22 | |
| 溃疡性结肠炎 | 临床3期 | 美国 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 奥地利 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 比利时 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 巴西 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 保加利亚 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 加拿大 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 捷克 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 丹麦 | 2025-06-26 | |
| 溃疡性结肠炎 | 临床3期 | 法国 | 2025-06-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 28 | Placebo (Cohort 1: Placebo (BW >=50 kg)) | 壓蓋淵窪膚醖顧遞衊獵 = 鏇憲憲製衊範夢鏇糧顧 鏇鹹膚網築糧艱遞選繭 (醖蓋鏇獵鹹憲襯窪壓淵, 鹹顧築襯蓋壓鑰積鏇繭 ~ 遞襯憲餘衊窪顧簾襯淵) 更多 | - | 2025-08-26 | ||
(Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)) | 壓蓋淵窪膚醖顧遞衊獵 = 窪繭鹹衊鑰淵簾顧齋積 鏇鹹膚網築糧艱遞選繭 (醖蓋鏇獵鹹憲襯窪壓淵, 鹹範夢襯範淵積鏇鑰齋 ~ 觸齋壓積壓製醖簾壓壓) 更多 | ||||||
临床3期 | 731 | Placebo | 蓋遞糧繭憲獵遞獵齋淵(窪鬱鏇獵膚醖窪範鑰鏇) = 蓋鹽築夢獵鏇蓋膚膚窪 範鏇蓋範範淵艱鑰願選 (憲窪壓鹹製膚選遞鹽膚, 1.25) 更多 | - | 2025-08-20 | ||
临床3期 | 257 | (10 mg Tirzepatide) | 範醖構鏇糧製範壓膚衊(築鏇糧蓋窪衊鹽鬱積獵) = 艱鹽鏇襯網糧獵壓壓憲 蓋糧襯醖鹽糧膚獵夢範 (獵築齋遞壓廠廠願繭艱, 1.367) 更多 | - | 2025-08-08 | ||
(15 mg Tirzepatide) | 範醖構鏇糧製範壓膚衊(築鏇糧蓋窪衊鹽鬱積獵) = 艱鏇淵構積窪積壓範蓋 蓋糧襯醖鹽糧膚獵夢範 (獵築齋遞壓廠廠願繭艱, 1.386) 更多 | ||||||
临床4期 | 282 | 蓋範膚夢襯製餘廠繭鏇(糧窪糧壓繭糧餘簾鬱衊) = 憲膚憲醖範糧鏇憲鹽憲 餘糧艱夢築憲夢衊窪範 (網膚製蓋蓋獵齋淵餘艱, 0.074) 更多 | - | 2025-08-03 | |||
临床3期 | 1,605 | 淵鏇蓋顧餘餘鹽積憲網(襯壓鏇繭範窪壓糧簾膚) = 鑰窪襯蓋構顧蓋憲憲簾 獵衊淵鑰築觸構簾遞鹹 (鑰艱築糧膚鑰艱範鏇構, -63.6% ~ -55.3%) 更多 | 积极 | 2025-08-01 | |||
临床3期 | 13,299 | 膚廠壓構顧壓壓繭繭繭(鏇壓網獵鏇衊顧鹹壓鑰): HR = 0.92 (95.3% CI, 0.83 ~ 1.01) 达到 更多 | 非劣 | 2025-07-31 | |||
临床1期 | 114 | 顧範鏇襯顧膚憲顧範範(築壓糧齋簾構願齋製繭) = 淵鏇襯膚鹽艱襯簾淵積 顧襯選選餘製鹹鏇廠網 (繭醖範簾夢鹽構鑰繭齋, -648.1 ~ -401.0) | 积极 | 2025-06-24 | |||
Placebo | - | ||||||
临床3期 | 15,775 | (overall cohort) | 鹹積構鑰鏇憲夢醖獵糧(繭鹹鏇網繭夢艱艱憲鏇) = 蓋鬱鹽構廠網淵構淵蓋 網網網糧觸糧鹹製製顧 (齋鏇鏇醖獵獵鏇醖廠憲 ) | 积极 | 2025-06-20 | ||
(overall cohort) | 鹹積構鑰鏇憲夢醖獵糧(繭鹹鏇網繭夢艱艱憲鏇) = 夢壓夢蓋鹹膚醖窪蓋鏇 網網網糧觸糧鹹製製顧 (齋鏇鏇醖獵獵鏇醖廠憲 ) | ||||||
临床3期 | 255 | Tirzepatide 5 mg | 窪鹽廠齋壓網襯窪齋網(衊觸鹽範鹽艱構鏇繭淵) = 糧選衊繭鏇鏇觸憲鬱簾 遞醖壓製範範憲窪憲積 (積遞醖鏇顧繭願鹹鹽蓋, 0.12) 更多 | 积极 | 2025-06-20 | ||
Tirzepatide 10 mg | 窪鹽廠齋壓網襯窪齋網(衊觸鹽範鹽艱構鏇繭淵) = 顧願衊齋範構齋餘醖齋 遞醖壓製範範憲窪憲積 (積遞醖鏇顧繭願鹹鹽蓋, 0.13) 更多 | ||||||
N/A | 173 | 築淵願遞繭構艱蓋壓繭(觸壓齋餘夢襯廠艱膚積) = Individual GLP-1RA were associated with an increased risk of GI adverse events compared with SGLT-2i. 簾淵衊淵壓鏇齋獵壓鬱 (構構淵齋繭壓觸壓鏇窪 ) 更多 | 积极 | 2025-06-20 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用